Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 diabetes mellitus by Jeremias, Allen et al.
Heart International 2009; volume 4:e7
[Heart International 2009; 4:e7] [page 25]
Effects of N-acetyl-cysteine on endothelial function and inflammation 





2 Robert C. Stanton,
2
Edward S. Horton,
2 David J. Cohen
3
1Division of Cardiology, Department of Internal Medicine, Stony Brook University Medical Center,
Stony Brook, NY; 
2Joslin Diabetes Center, Harvard Medical School, Boston, MA; 
3Saint Luke's Mid
America Heart Institute, Kansas City, MO, USA
Abstract 
Endothelial dysfunction has been associat-
ed with premature vascular disease. There is
increasing data that N-acetyl-cysteine (NAC)
may prevent or improve endothelial dysfunc-
tion. The aim of this study was to assess the
effects  of  NAC  on  endothelial  function  in
patients with type 2 diabetes mellitus, a popu-
lation at high risk for endothelial dysfunction.
Twenty-four  patients  with  diabetes  mellitus
were assigned randomly to initial therapy with
either 900 mg NAC or placebo twice daily in a
double-blind,  cross-over  study  design.  Flow-
mediated vasodilation (FMD) of the brachial
artery  was  assessed  at  baseline,  after  four
weeks of therapy, after a four-week wash-out
period, and after another four weeks on the
opposite treatment. Plasma and red blood cell
glutathione levels and high-sensitivity C-reac-
tive protein (CRP) were measured at all four
visits.  At  baseline,  FMD  was  moderately
impaired  (3.7±2.9%).  There  was  no  signifi-
cant change in FMD after four weeks of NAC
therapy as compared to placebo (0.1±3.6% vs.
1.2±4.2%). Similarly, there was no significant
change in glutathione levels. However, median
CRP decreased from 2.35 to 2.14 mg/L during
NAC therapy (p=0.04), while it increased from
2.24 to 2.65 mg/L with placebo. No side effects
were  noted  during  the  treatment  period.  In
this  double-blind,  randomized  cross-over
study, four weeks of oral NAC therapy failed to
improve  endothelial  dysfunction  in  patients
with diabetes mellitus. However, NAC therapy
decreased  CRP  levels,  suggesting  that  this
compound may have some efficacy in reducing
systemic inflammation. 
Introduction
The endothelium is central to the regula-
tion of vascular tone, inflammation, platelet
aggregation, and lipoprotein oxidation by the
production of nitric oxide (NO).
1 The reduc-
tion of NO bioavailability is a consequence of
endothelial dysfunction and thought to be an
early event in the pathogenesis of atheroscle-
rosis.
2 Hyperglycemia
3 and insulin resistance
4
have been associated with severe endothelial
dysfunction in humans. Studies evaluating the
effect  of  antioxidant  therapy  on  endothelial
function,  including  vitamin  C  and  E  and
probucol, have been encouraging.
5-7 However,
long-term  therapy  with  vitamin  E  does  not
seem to have any beneficial effect in improv-
ing endothelial function.
8
Reduced  thiols  are  molecules  with  a
sulfhydryl  group  that  have  many  biological
functions,  including  scavenging  oxygen-free
radicals,  acting  as  cofactors  for  enzymatic
reactions, and modifying the half-life of NO by
forming NO adducts.
9 The thiol N-acetyl-cys-
teine (NAC) may potentiate the activity of NO
directly  by  forming  more  biologically  active
adducts,  scavenging  free  radicals,  and  pre-
venting  NO  oxidation  and  degradation.  In
addition, NAC stimulates the synthesis of glu-
tathione, which acts as a nucleophilic scav-
enger and as an enzyme-catalyzed antioxidant
in the event of oxidative tissue injury.
10
The aim of this study was to evaluate the
effect of NAC on endothelial function as meas-
ured by flow-mediated vasodilation (FMD) of
the  brachial  artery  and  the  degree  of  glu-
tathione  induction  by  NAC  in  patients  with
type 2 diabetes, a patient population at high
risk for endothelial dysfunction. 
Materials and Methods
General study design
We  performed  a  prospective,  randomized,
placebo-controlled,  double-blind,  cross-over
study  of  the  change  in  vascular  endothelial
function after four weeks of treatment with
NAC  and  four  weeks  of  placebo  in  patients
with  type  2  diabetes  mellitus.  Endothelial
function was assessed in each individual by
FMD of the brachial artery at four different
time points: prior to therapy, after four weeks
of NAC or placebo, after a wash-out period of
four weeks, and after four weeks of the oppo-
site  treatment.  Compliance  with  the  study
medication was assessed by pill count. In addi-
tion, plasma and red blood cell total, reduced
glutathione  levels,  and  high-sensitivity  C-
reactive protein (CRP) were measured in each
patient at all four different time points. The
protocol  was  approved  by  the  institutional
review board, and all participants gave written
informed consent.
Patient population
A total of 24 patients were included in the
study.  Subjects  were  enrolled  if  they  were
between the ages of 21 and 80 years and diag-
nosed with type 2 diabetes mellitus within the
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past 10 years. Diabetes was defined according
to  the  recommendations  of  the  American
Diabetes Association Expert Committee on the
Classification  and  Diagnosis  of  Diabetes.
11
Only patients on a stable medical regimen for
diabetes for at least two months prior to study
entry were enrolled and patients were encour-
aged  to  continue  on  the  same  regimen
throughout the study, unless urgent changes
were required. Patients were on either insulin
or  oral  anti-hyperglycemic  therapy  with  a
hemoglobin A1c of 6.0-9.5%.
To  avoid  confounding  factors  known  to
affect endothelial function and minimize con-
founding  that  arises  from  the  cross-over
design, patients were excluded if they met any
of the following criteria: uncontrolled diabetes
requiring frequent dose adjustments of med-
ical therapy or noncompliance with the med-
ical regimen, congestive heart failure, anginal
symptoms, exercise-induced ischemia (if prior
stress testing were available), ischemic EKG
changes at rest, prior myocardial infarction or
coronary revascularization procedures (includ-
ing percutaneous coronary interventions and
coronary artery bypass grafting), and peripher-
al  vascular  disease.  Other  exclusion  criteria
were significant comorbidities such as renal or
hepatic insufficiency. 
A  general  physical  examination  was  per-
formed  by  a  study  physician  prior  to  enroll-
ment. Subjects were studied at all visits after a
12-hour fast. Participants were asked not to
take  their  diabetes  medications  (sulfonl-
ureas) for 12 hours prior to any of the studies,
and  those  participants  taking  insulin  were
asked to omit the rapid-acting insulin on the
morning of each visit.
Laboratory data 
Baseline  laboratory  data  included  plasma
glucose,  total  serum  cholesterol,  low-density
lipoprotein  (LDL)  cholesterol,  high-density
lipoprotein  (HDL)  cholesterol,  and  triglyc-
erides  (Synchron  CX  analyzer,  Beckman/
Coulter, Brea, CA, USA). The hemoglobin A1c
was  determined  in  whole  blood  using  ion-
exchange  HPLC  (Tosoh  2.2,  Tokyo,  Japan).
CRP was measured using a commercially avail-
able kit from Diagnostic Products Corporation
(Los Angeles, CA, USA). This High Sensitivity
CRP  Kit  (Catalog  #LKCR1)  was  run  on  an
Immulite  Analyzer  and  is  based  on  a  solid-
phase,  chemiluminescent  immunometric
assay methodology. Functional or active PAI-1
was quantitated using an ELISA kit (Catalog
#PI  90)  from  Oxford  Biomedical  Research
(Oxford, MI, USA). Levels of interleukin-6 (IL-
6; Catalog #D6050), soluble intracellular adhe-
sion molecule (ICAM-1) (Catalog #BBE 1B),
and  soluble  vascular  cell  adhesion  molecule
(VCAM-1) (Catalog #DVC00) were quantitated
using  ELISA  kits  from  R&D  Systems
(Minneapolis, MN, USA). GSH was measured
by  a  commercially  available  assay  (Cayman
Chemical, Ann Arbor, MI, USA) that utilizes a
carefully  optimized  enzymatic  recycling
method, using glutathione reductase, for the
quantification of GSH. The sulfhydryl group of
GSH reacts with 5,5’-dithiobis-2-nitrobenzoic
acid (DTNB, Ellman’s reagent), and produces a
yellow-colored  5-thio-2-nitrobenzoic  acid
(TNB). The mixed disulfide, GSTNB (between
GSH and TNB) that is produced concomitantly,
is reduced by glutathione reductase to recycle
the GSH and produce more TNB. The rate of
TNB production is directly proportional to this
recycling  reaction,  which  is  in  turn  directly
proportional to the concentration of GSH in the
sample.  Measurement  of  the  absorbance  of
TNB at 405 or 414 nm provides an accurate
estimation of GSH in the sample.
Medical therapy
Patients  were  maintained  on  their  usual
medical regimen throughout the study period.
Changes  to  medications  were  made  only  if
absolutely necessary at the discretion of the
treating physician. After the baseline evalua-
tion, all patients were randomized to NAC 900
mg orally twice per day or placebo for a period
of four weeks. Following a four-week wash-out
period, the opposite therapy was administered
for another four weeks. NAC was provided by
BioAdvantex  Pharma  Inc.  (Mississauga,  ON,
Canada) and tested for purity. Patient compli-
ance was assessed by pill count and telephone
confirmation and found to be >90%. 
Endothelial reactivity testing
To assess the endothelium-dependent reac-
tivity  in  the  macrocirculation,  FMD  of  the
brachial artery was measured by using high-
resolution ultrasound with a 10.0-MHz linear
array  transducer  and  an  HDI  Ultramark-9
System  (Advanced  Technology  Laboratories,
Bothel, WA, USA). All measurements were con-
ducted in accordance with recently published
guidelines.
12 Measurements were made in the
right  arm  in  a  temperature-controlled  room
(22°C) after a 15-minute equilibration period
with the subject resting in the supine position.
Studies were performed after a 12-hour fast.
Blood pressure and heart rate were monitored
in the contralateral arm before and after the
brachial artery measurements and prior to and
after  nitroglycerin  administration.  Once  an
acceptable  image  of  the  brachial  artery  was
obtained,  the  arm  was  immobilized  in  that
position throughout the study. Subsequently, a
pneumatic tourniquet was placed around the
forearm distal to the target vessel and inflated
Table 2. Baseline medical therapy of the study population.
Insulin therapy 3 (13%)
Metformin therapy 16 (67%)
Thiazolidenedione therapy 4 (17%)
Diet-controlled alone 2 (8%)
Lipid-lowering therapy 15 (63%)
Angiotensin converting enzyme inhibitor 15 (63%)
Aspirin therapy 15 (63%)
Table 1. Baseline characteristics of the study population.
24 patients
Female gender 13(54%)
Active smoker 3 (13%)
Former smoker 8 (33%)
Dyslipidemia* 21 (88%)
Systemic hypertension 17 (71%)
No. of years of diabetes mellitus 5.1±2.4
Body mass index 33.3±7.0
Total cholesterol (mg/dL) 159±45
Low-density lipoprotein cholesterol (mg/dL) 91±26
High-density lipoprotein cholesterol (mg/dL) 42±11
Triglyceride (mg/dL) 193±118
Hemoglobin A1c (%) 7.3±0.9
Fasting glucose (mg/dL) 154±63
*Defined as total cholesterol >200 mg/dL or on lipid-lowering therapy. Article
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to 50 mmHg above the subject’s systolic blood
pressure  for  a  period  of  five  minutes.  One
minute  after  sudden  deflation,  the  brachial
artery  dimensions  were  measured  by  ultra-
sound and compared with the baseline vessel
dimensions. Endothelium-independent vasodi-
lation was assessed by studying brachial artery
diameter  changes  three  minutes  after  the
administration of 0.4 mg of sublingual nitro-
glycerin. This test was performed 15 minutes
after  the  reactive  hyperemia  test  and  after
obtaining  a  new  baseline  reading.  Previous
research  showed  satisfactory  reliability  and
repeatability of this technique.
13
Statistical methods
Continuous  variables  are  described  as
mean±standard  deviation  while  categorical
variables are described as proportions. The pri-
mary endpoint of the study was the change in
FMD (expressed as % change) after four weeks
of NAC and placebo therapy, respectively, and
was  compared  using  the  sign-rank  test.
Secondary endpoints included changes in glu-
tathione and CRP levels during NAC and place-
bo  therapy.  Similar  to  the  primary  endpoint
analysis, a Wilcoxon signed-rank test was used
to  determine  statistical  significance  of  any
observed  differences.  Comparisons  across
groups were made using the Student’s t-test.
The  study  had  80%  power  to  detect  a  3.3%
change in FMD at p<0.05. Results were consid-
ered statistically significant at p<0.05. All sta-
tistical analyses were performed using Stata




The mean duration of diabetes was 5.1±2.4
years (range 1-10 years). Baseline characteris-
tics of the study population are presented in
Table 1. Five (21%) patients were on insulin
therapy,  2  (8%)  were  controlled  with  diet
alone, while the remainder (71%) were on oral
anti-diabetic therapy (Table 2). 
NAC and FMD 
At baseline, FMD demonstrated moderately
impaired  endothelial  function  (3.7±2.9%).
There was no significant change in FMD after
four  weeks  of  NAC  therapy  as  compared  to
placebo (0.05±3.6 vs. 1.2±4.2%; Figure 1). As
expected,  endothelial-independent  vasodila-
tion  (induced  by  nitroglycerin)  was  signifi-
cantly larger than FMD at baseline (8.5±4.1 vs.
3.7±2.9%, p<0.001). NAC therapy did not affect
endothelial-independent  vasodilation  signifi-
cantly (9.0±4.8 vs. 9.1±4.8%). There was no
effect of treatment order. No side effects were
noted during the treatment period. 
Laboratory testing
There  was  no  significant  change  in  total
plasma  glutathione  levels  from  baseline  to
posttherapy  (3.1±0.6  vs.  2.9±0.6  μM).
Similarly,  total  (106.9±47.7  vs.  107.9±50.9
μM)  and  reduced  (94.8±38.5  vs.  95.2±38.4
μM) red blood cell glutathione levels (referred
to as packed red blood cells) did not change
significantly during treatment.
Median CRP decreased from 2.35 mg/L (25-
75%  quartiles:  1.02-6.87  mg/L)  to  2.14  mg/L
(25-75%  quartiles:  0.97-7.01  mg/L,  p=0.04;
Figure 2) during NAC therapy, while it numer-
ically increased from 2.24 mg/L (25-75% quar-
tiles:  1.82-6.85  mg/L)  to  2.65  mg/L  (25-75%
quartiles: 1.51-6.50 mg/L, p=0.40) with place-
bo.  When  comparing  the  median  change  in
CRP during NAC versus placebo therapy, there
was  a  nonsignificant  trend  toward  a  CRP
decrease  with  NAC  (-0.18  vs.  0.21  mg/L,
p=0.14). When the analysis was repeated after
excluding one patient who had an infection at
the  baseline  measurement  of  the  placebo
phase (CRP of 41.2 mg/L), the overall change
Table 3. Inflammatory and endothelial markers.
Marker Pre-NAC Post-NAC p Pre-placebo Post-placebo p
IL-6 3.3 (3.0-3.6) 3.2 (2.8-3.6) 0.27 3.2 (2.9-3.5) 3.0 (2.7-3.4) 0.28
VCAM-1 732(593-870) 717 (580-854 0.52 709 (578-840) 703 (571-836) 0.82
ICAM-1 262(230-295) 258 (225-292) 0.88 264 (235-293) 250 (218-281) 0.02
PAI-1 36.5(21.9-51) 38.6(20.6-56.6) 0.88 40.9(24.4-57.5) 49.1(27.9-70.3) 0.13
Data presented as median (95% confidence interval). 
Figure 1. Changes in brachial artery flow-mediated vasodilation (FMD) and nitroglycer-
ine (NTG) induced vasodilation before and after therapy with N-Acetyl-cysteine (NAC)
and placebo.
Figure 2. Individual changes of C-reactive protein before and after treatment with NAC
and placebo. Article
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in CRP was -0.18 mg/L during NAC and 0.23
mg/L during placebo therapy (p=0.053). 
Other inflammatory and endothelial mark-
ers, including IL-6, PAI-1, ICAM-1, and VCAM-
1, did not change significantly throughout the
treatment period (Table 3). 
Discussion
This  double-blind,  randomized  cross-over
study showed no improvement in FMD after
four  weeks  of  NAC  therapy  compared  with
placebo. This could be explained by the lack of
glutathione induction, which has been shown
to have favorable effects on endothelial func-
tion. However, NAC did have a modest effect in
decreasing  CRP,  suggesting  that  this  com-
pound may have some efficacy in reducing sys-
temic inflammation. 
A few reports have studied the effect of NAC
on vascular endothelial function. In a recent
study by Andrews et al., NAC was administered
into  the  coronary  and  femoral  arteries  of
patients  with  and  without  atherosclerosis.
14
NAC  potentiated  acteylcholine-mediated  vas-
cular  dilation,  indicating  its  usefulness  in
improving  endothelial  function.  In  another
study,  intravenous  infusion  of  NAC  showed
significant  vasodilation  in  small  epicardial
arteries and augmented coronary blood flow.
15
In an animal model of diabetes mellitus, the
oral administration of NAC completely prevent-
ed the development of endothelial dysfunction
independent  of  the  degree  of  glycemic  con-
trol.
16
The present study failed to show any benefi-
cial effects of NAC on endothelial function in
this  high-risk  diabetic  patient  population,
despite  striking  endothelial  dysfunction  at
baseline in the majority of patients. The most
likely explanation for the lack of effect is that
NAC did not increase glutathione levels suffi-
ciently. Glutathione acts as a nucleophilic scav-
enger and as an enzyme-catalyzed antioxidant
in  the  event  of  oxidative  tissue  injury.
10
Oxygen-free radicals, responsible for inactivat-
ing  NO,  are  scavenged  from  plasma  or
endothelial cells by both NAC and glutathione,
thereby increasing the bioavailability of NO. In
particular,  intracellular  reduced  glutathione
has a vital role in protecting endothelial cells
from  oxygen-free  radicals
17 and  improves
endothelial  vasomotor  response  to  acetyl-
choline when directly infused into the coro-
nary artery.
18 Recently, a low level of red blood
cell glutathione peroxidase-1 activity has been
associated with an increased risk of cardiovas-
cular events in a patient population with estab-
lished coronary artery disease, suggesting the
importance  of  glutathione  in  cardiovascular
disease  prevention.
19 Glutathione  is  synthe-
sized  intracellularly  from  the  amino  acids
glycine, glutamate, and cysteine. Since the for-
mer two are abundantly available in the intra-
cellular space, an adequate supply of cysteine
into the cell becomes the rate-limiting step in
the synthesis of glutathione. 
In a preliminary animal study, we demon-
strated that oral NAC administration substan-
tially increased both glutathione and cysteine
levels.
20 It is unclear why NAC supplementation
failed to increase plasma and red blood cell
glutathione levels in this study but one expla-
nation  could  be  that  glutathione  cannot  be
increased  to  supra-normal  levels.  Previously
published studies have demonstrated that NAC
increases  glutathione  in  patients  with
decreased levels but no data exists on increas-
ing glutathione above normal levels. For exam-
ple, in one study in patients with the human
immune-deficiency virus, a condition associat-
ed  with  substantially  decreased  glutathione
levels, the oral administration of NAC replen-
ished glutathione to normal levels.
21 Another
potential explanation for the lack of increase
in  glutathione  levels  could  be  the  reduced
bioavailability of NAC during supplementation.
There  are  a  number  of  reports  indicating
that  therapy  with  NAC  may  have  beneficial
effects in suppressing systemic inflammation,
a condition that is closely linked to the devel-
opment  of  atherosclerosis.
22 For  instance,
VCAM-1 enables the attachment of circulating
cells  to  the  endothelium  and  thus  promotes
intravascular accumulation of various inflam-
matory  cells.
23 NAC  effectively  decreased
VCAM-1  expression  in  a  diabetic  population
that is prone to elevated plasma soluble VCAM-
1  concentrations.
24 Similarly,  in  patients
undergoing  liver  transplantation,  high-dose
NAC administration significantly inhibited the
increase  in  both  ICAM-1  and  VCAM-1  after
reperfusion.
25 In  cell  cultures,  Faruqi  et  al.
showed that NAC inhibited IL-1-induced mRNA
as well as cell surface expression of both E-
selectin and VCAM-1, suggesting potent anti-
inflammatory  effects  of  NAC.
26 This  study
demonstrated no significant effect of NAC on
ICAM-1, VCAM-1, and IL-6 but showed a mod-
est decrease in CRP levels after four weeks of
therapy. However, after the exclusion of one
patient with severely elevated CRP secondary
to an infection, there was only a trend toward
CRP reduction with NAC (p=0.053). Given that
relatively few therapies have been shown to
reduce CRP to date,
27 NAC may represent an
addition to the armamentarium of agents that
can lower systemic inflammation. Whether the
extent of CRP reduction observed in this study
translates into clinically measurable benefits
is unknown, but a recent study of 134 patients
with  end-stage  renal  disease  suggests  that
NAC may be a clinically useful agent.
28 In that
study, patients were randomized to either NAC
or placebo and found to have a 40% lower inci-
dence of cardiac events, ischemic strokes, and
peripheral vascular disease in the NAC treated
group after a median follow-up of 14 months. A
larger study linking the reduction in CRP with
clinical outcomes may provide useful informa-
tion in the future. 
In  conclusion,  a  four-week  course  of  oral
NAC therapy did not improve endothelial dys-
function in patients with diabetes mellitus and
clinically  absent  cardiovascular  disease.
However, NAC therapy significantly decreased
CRP levels in this challenging patient popula-
tion. Further study is warranted to confirm this
finding. 
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